Correlation of endogenous opioid peptides in diagnosis and treatment of depression

doi:10.16138/j.1673-6087.2024.06.07

Abstract

Abstract:

Objective To explore the difference of plasma endogenous opioid peptide level in patients with depression and its relationship with the severity of depression or anxiety, and analyze whether endogenous opioid peptide is helpful to the diagnosis and treatment of depression. Methods A total of 96 patients with depression who visited our hospital from June 2020 to February 2023 were enrolled as the depression group, and 50 healthy subjects were recruited as the control group. General demographic and clinical data [Hamilton depression scale 17(HAMD-17), Hamilton anxiety scale 14(HAMA-14), inventory of depressive symptomatology 30(IDS-30)] were collected. Peripheral blood was collected, plasma was extracted, and plasma β-endorphin (β-EP) and enkephalin (ENK) were compared between the two groups using enzyme-linked immunosorbent assay (ELISA). Due to the repeated impact of the epidemic, only 28 patients agreed to follow-up studies and blood collection plans. During the follow-up period, the treatment was in accordance with the plan made by outpatient physician, and there was not any research intervention. After 8 weeks of follow-up, 24 patients finished the studies, and their clinical data and blood samples were collected and compared. Results The plasma β-EP level in depression group was significantly higher than that in control group [49.48（36.79,61.14） ng/mL vs 30.84（23.51,38.14）ng/mL， P<0.05], while the plasma ENK level was significantly lower than that in control group [15.85（10.51,19.56）ng/mL vs 23.72（21.44,26.98）ng/mL， P<0.05]. Correlation analysis showed that there was no significant correlation between β-EP and ENK levels at baseline and the scores of the three scales (P > 0.05). There were no significant differences in plasma β-EP and ENK levels between cured group and non-cured group after 8-week of treatment compared to baseline (P > 0.05). Conclusions β-EP and ENK are expected to be biomarkers of depression.

Key words: Endogenous opioid peptides, Depression, Hamilton depression scale, Hamilton anxiety scale

CLC Number:

R749.7

GAN Xinyi, LIU Wanying, ZHANG Fuxu, BAI Yujie, HU Hao, GUO Qian, LIU Xiaohua. Correlation of endogenous opioid peptides in diagnosis and treatment of depression[J]. Journal of Internal Medicine Concepts & Practice, 2024, 19(06): 393-398.

Figures/Tables 6

Table 1

Table 2

Table 3

Table 4

Table 5

Table 6

References 20

[1]	Tolentino JC, Schmidt SL. DSM-5 criteria and depression severity: implications for clinical practice[J] .Front Psychiatry, 2018, 9:450. doi: 10.3389/fpsyt.2018.00450 pmid: 30333763
[2]	Grover S, Adarsh H. A comparative study of prevalence of mixed features in patients with unipolar and bipolar depression[J]. Asian J Psychiatr, 2023, 81:103439.
[3]	Mitchell AJ, Vaze A, Rao S. Clinical diagnosis of depression in primary care[J]. Lancet, 2009, 374(9690):609-619. doi: 10.1016/S0140-6736(09)60879-5 pmid: 19640579
[4]	吴宁, 卢关伊, 杨磊, 等. 阿片受体作用系统与抑郁症发病及干预研究进展[J]. 中国药理学与病理学杂志, 2020, 34(9):641-655.
[5]	Edgardo Falcon, Kaitlyn Maier, Shivon A Robinson, et al. Effects of buprenorphine on behavioral tests for antidepressant and anxiolytic drugs in mice[J]. Psychopharmacology (Berl), 2015, 232(5):907-915.
[6]	Vázquez G, Lolich M, Cabrera C, et al. Mixed symptoms inmajor depressive and bipolar disorders: a systematic review[J]. J Affect Disord, 2018, 225:756-760.
[7]	Rush AJ, Trivedi MH, Wisniewski SR, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report[J]. Am J Psychiartry, 2006, 163(11):1905-1917.
[8]	王祖承. 难治性精神疾病[M]. 上海: 上海科学技术出版社, 2007:137-138.
[9]	Berton O, Nestler EJ. New approaches to antidepressant drug discovery: beyond monoamines[J]. Nat Rev Neurosci, 2006, 7(2):137-151. doi: 10.1038/nrn1846 pmid: 16429123
[10]	Isacsson G, Rich CL. Antidepressant drugs and the risk of suicide in children and adolescents[J]. Paediatr Drugs, 2014, 16(2):115-122. doi: 10.1007/s40272-013-0061-1 pmid: 24452997
[11]	Marasine NR, Sankhi S, Lamichhane R, et al. Use of antidepressants among patients diagnosed with depression: a scoping review[J]. Biomed Res Int, 2021, 2021:6699028.
[12]	Blackburn TP. Depression disorders: treatment failures and poor prognosis over the last 50 years[J]. Pharmacol Res Perspect, 2019, 7(3):e00472.
[13]	Browne CA, Lucki I. T argeting opioid dysregulation in depression for the development of novel therapeutics[J]. Pharmacol Ther, 2019, 201:51-76.
[14]	Hilario BF, Roaberto FF, Laura C, et al. The active model of self-harming (non-suicidal and suicidal) behaviour[J]. Front Psychiatry, 2016, 7(4):8-14.
[15]	Kennedy SE, Koeppe RA, Young EA, et al. Dysregulation of endogenous opioid emotion regulation circuitry in major depression in women[J]. Arch Gen Psychiatry, 2006, 63:1199-1208. doi: 10.1001/archpsyc.63.11.1199 pmid: 17088500
[16]	Navines R, Martin-Santos R, Gomez-Gil E, et al. Interaction between serotonin 5-HT1A receptors and beta-endorphins modulates antidepressant response[J]. Prog Neuropsychopharmacol Biol Psychiatry, 2008, 32(8):1804-1809.
[17]	Djurovic D, Milic-Askrabic J, Majkic-Singh N. Serum beta-endorphin level in patients with depression on fluvoxamine[J]. Farmaco, 1999, 54(3):130-133. pmid: 10371024
[18]	张宁, 侯钢, 方群. 抑郁症的神经内分泌学初步研究[J]. 临床精神医学杂志, 2002,(4):208-209.
[19]	Susan EK, Robert AK, Elizabeth AY, et al. Dysregulation of endogenous opioid emotion regulation circuitry in major depression in women[J]. Arch Gen Psychiatry, 2006, 63(11):1199-1208. doi: 10.1001/archpsyc.63.11.1199 pmid: 17088500
[20]	Bodkin JA, Zornberg GL, Lukas SE, et al. Buprenorphine treatment of refractory depression[J]. J Clin Psychopharmacol, 1995, 15(1):49-57. doi: 10.1097/00004714-199502000-00008 pmid: 7714228

项目	对照组（n=50）	抑郁症组（n=96）	χ²/t	P
性别(男/女)[n(%)]	13(26)/37(74)	23(24)/73(76)	0.074	0.786
年龄(岁)	28.48±6.06	28.70±9.18	0.172	0.864
受教育年限(年)	16.64±3.21	14.56±2.96	-3.906	<0.001
HAMD-17总分(分)	-	24.13±4.84	-	-
HAMA-14总分(分)	-	25.99±7.79	-	-
IDS-30总分(分)	-	42.54±10.76	-	-

检测指标	对照组（n=50）	抑郁症组（n=96）	Z	P
β-EP	30.84（23.51,38.14）	49.48（36.79,61.14）	-6.939	<0.001
ENK	23.72（21.44,26.98）	15.85（10.51,19.56）	-7.899	<0.001

指标		HAMD-17总分	HAMA-14总分	IDS-SR30总分
β-EP	r	-0.041	0.196	-0.029
	P	0.691	0.056	0.781
ENK	r	0.196	0.070	0.140
	P	0.055	0.499	0.174

项目	痊愈组	未痊愈组	t	P
HAMD-17总分	22.58±5.05	23.08±3.12	0.292	0.773
HAMA-14总分	23.42±6.44	25.17±7.07	0.634	0.533
IDS-30总分	37.58±10.56	46.75±9.96	2.188	0.040

项目	痊愈组	未痊愈组	Z/t	P
HAMD-17	5.00（3.00，5.75）	8.50（8.00，14.50）	-4.201	<0.001
HAMA	5.50（3.25，7.50）	9.50（7.50，16.00）	-2.463	0.014
IDS-30	13.00（10.00，19.25）	19.50（13.75，30.50）	-1.995	0.046